ABII » Topics » Impairment Charge

These excerpts taken from the ABII 10-K filed Mar 12, 2010.

Impairment Charge

We assess for potential impairment of our long-lived assets whenever events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. A long-lived asset is impaired when the carrying value of the asset is determined not to be recoverable and the carrying amount exceeds the asset’s fair value. For the year ended December 31, 2009, we recorded an impairment charge of $14.0 million on property, plant and equipment for which the intended use had changed. For the year ended December 31, 2008, we recognized an impairment charge $9.2 million as a result of an anticipated sale of certain property, plant and equipment.

 

44


Table of Contents

Impairment Charge

We review our property, plant and equipment for impairment whenever events or changes in circumstances indicate that the carrying value of the assets might not be recoverable. For the year ended December 31, 2009, based on market valuations, we recorded an impairment charge of $14.0 million on assets for which the intended use had changed. For the year ended December 31, 2008, we recognized an impairment charge of $9.2 million as a result of an anticipated sale of certain property, plant and equipment.

These excerpts taken from the ABII 10-K filed Mar 6, 2009.

Impairment Charge

We recorded a property, plant and equipment impairment charge totaling $9.2 million as a result of an anticipated sale of certain property, plant and equipment,.

Impairment Charge

FACE="Times New Roman" SIZE="2">We recorded a property, plant and equipment impairment charge totaling $9.2 million as a result of an anticipated sale of certain property, plant and equipment,.

STYLE="margin-top:18px;margin-bottom:0px; margin-left:2%">Equity Income in Drug Source Company, LLC

FACE="Times New Roman" SIZE="2">Drug Source Company, LLC is 50% owned by us and is a selling agent of raw material to the pharmaceutical industry. Our investment in Drug Source Company is intended to both generate a return on our investment and to
strengthen our future strategic sourcing capabilities over time. Because our 50% ownership interest in Drug Source Company does not provide financial or operational control of Drug Source Company, we account for our interest in Drug Source Company
under the equity method. Our equity income in Drug Source Company for the years ended December 31, 2008, 2007 and 2006 was $0.9 million, $3.8 million and $2.8 million, respectively. The decrease in 2008 was due primarily to higher sales of
lower margin products.

Impairment Charge

We review our property, plant and equipment for impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. For the year ended December 31, 2008, we recorded an asset impairment charge of $9.2 million as a result of an anticipated sale of certain property, plant and equipment. The amount is included in “impairment charge” in the consolidated and combined statements of operations.

Impairment Charge

STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%">We review our property, plant and equipment for impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may
not be recoverable. For the year ended December 31, 2008, we recorded an asset impairment charge of $9.2 million as a result of an anticipated sale of certain property, plant and equipment. The amount is included in “impairment
charge” in the consolidated and combined statements of operations.

This excerpt taken from the ABII 10-Q filed Nov 14, 2008.

Impairment Charge

As a result of an anticipated sale of certain property, plant and equipment, we recorded a property, plant and equipment impairment charge totaling $9.2 million.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki